This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVS? (Revised)
by Rajshree Sipani
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
UNHPositive Net Change CVSPositive Net Change
healthcare hmo insurance medical smart-health
EHC Expands in Tennessee Via New JV Facility With Vanderbilt Health
by Zacks Equity Research
Encompass Health teams up with Vanderbilt Health to open a new 40-bed inpatient rehabilitation hospital in Tennessee, targeting a 2028 launch.
BSXNegative Net Change ISRGNegative Net Change ENSGNegative Net Change EHCPositive Net Change
medical
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026
by Bryan Hayes
Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.
LLYNegative Net Change
artificial-intelligence earnings investing large-cap medical oncology-screening pharmaceuticals smart-health
Battle of Benefits: Will UNH Deliver the Bigger Dose or CVH?
by Rajshree Sipani
CVS's rising margins, stronger guidance and sharper valuation edge make it stand out in the UNH vs. CVS upside debate.
UNHPositive Net Change CVSPositive Net Change
healthcare hmo insurance medical smart-health
Healthcare Equity ETF (GDOC) Hits Fresh 52-Week High
by Zacks Equity Research
GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.
LLYNegative Net Change GDOCPositive Net Change
etfs medical
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
by Sundeep Ganoria
JAZZ leverages Epidiolex's rising sales and its broad drug portfolio to strengthen its position in the evolving medical cannabis market.
JAZZNegative Net Change TLRYPositive Net Change VRNOPositive Net Change
biotechs marijuana medical pot-stocks
GEHC Stock Gains Post Latest Launch to Optimize Radiology Workflows
by Zacks Equity Research
GE HealthCare unveils Genesis Radiology Workspace, aiming to streamline imaging workflows and boost diagnostic precision.
BSXNegative Net Change IDXXNegative Net Change CORNegative Net Change GEHCPositive Net Change
medical medical-devices
New Clinical Evidence Bolsters Hologic's Breast Cancer Technologies
by Moumi Mondal
HOLX is set to present new real-world data at RSNA 2025, showing how its AI-driven breast imaging tools boost workflow without sacrificing detection.
HOLXNegative Net Change QGENNegative Net Change GEHCPositive Net Change
medical medical-devices
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
SNYNegative Net Change GILDPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
From Hospitals to ASCs: Will Refurbished Xi Systems Broaden ISRG's Reach?
by Indrajit Bandyopadhyay
ISRG leverages refurbished Xi systems to reach cost-sensitive markets and expand access beyond hospitals.
ISRGNegative Net Change STXSNegative Net Change ZBHPositive Net Change
medical medical-devices
Company News for Nov 26, 2025
by Zacks Equity Research
Companies In The News Are: A, KEYS, SMTC, SYM.
ANegative Net Change SMTCPositive Net Change KEYSPositive Net Change SYMPositive Net Change
medical semiconductor tech-stocks
Top Analyst Reports for NVIDIA, AT&T & Amgen
by Mark Vickery
NVIDIA's data center gains, AT&T's wireless momentum, and Amgen's product strength headline today's standout analyst reports.
TNegative Net Change AMGNPositive Net Change EPositive Net Change NVDAPositive Net Change GMPositive Net Change LHXNegative Net Change
communications medical semiconductor
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMYPositive Net Change JNJPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
by Zacks Equity Research
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
NVSPositive Net Change BAYRYNegative Net Change FOLDPositive Net Change RNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
by Zacks Equity Research
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
SRPTPositive Net Change RNAPositive Net Change ARWRPositive Net Change PEPGPositive Net Change
biotechs gene-editing gene-therapy medical
Is UNH's Hybrid Care Strategy Reshaping the Health System Playbook?
by Zacks Equity Research
UnitedHealth pushes its hybrid care model forward, merging digital tools with in-person care as it extends this approach across global markets.
UNHPositive Net Change HUMPositive Net Change ELVPositive Net Change
medical
Agilent Q4 Earnings Match Estimates, Revenues Up Y/Y, Shares Fall
by Zacks Equity Research
A report higher Q4 revenues and lifts its 2026 outlook, yet the stock slips as margins narrow across key business segments.
MDTNegative Net Change ANegative Net Change BLFSNegative Net Change PAHCNegative Net Change
earnings medical
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve
by Debanjana Dey
HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.
MEDPositive Net Change HIMSPositive Net Change TEMPositive Net Change
medical medical-devices
Take SEM Off the Menu? Executive Chairman Gives Premium Offer
by Zacks Equity Research
Select Medical draws investor focus as its executive chairman offers a take-private idea at up to a 15.6% premium to the latest close.
SEMNegative Net Change PNTGPositive Net Change AVAHPositive Net Change
medical
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
by Zacks Equity Research
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
NVOPositive Net Change ADMANegative Net Change EDITPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
by Zacks Equity Research
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
BIIBNegative Net Change ADMANegative Net Change EDITPositive Net Change ARQTPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Do Options Traders Know Something About Bausch Health Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BHC stock based on the movements in the options market lately.
BHCNegative Net Change
medical
Boston Scientific's Margins Strengthen in Q3: What's Driving It?
by Moumi Mondal
BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.
ABTPositive Net Change BSXNegative Net Change GEHCPositive Net Change
medical medical-devices
CVS vs. WMT: Which Retail Pharmacy Powerhouse Looks Stronger Now?
by Moumi Mondal
CVS gains momentum with record revenues, stronger guidance and a cheaper valuation, standing out in the retail pharmacy comparison with WMT.
WMTPositive Net Change CVSPositive Net Change
medical medical-devices
Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How
by Sridatri Sarkar
TEM's surging Insights revenues, new contracts and expanded AI capabilities highlight its shift toward scalable data-driven growth.
ICLRPositive Net Change SOPHPositive Net Change TEMPositive Net Change
medical